Annual Working Capital
$189.62 M
-$60.70 M-24.25%
31 December 2023
Summary:
Monte Rosa Therapeutics annual working capital is currently $189.62 million, with the most recent change of -$60.70 million (-24.25%) on 31 December 2023. During the last 3 years, it has risen by +$175.30 million (+1224.53%). GLUE annual working capital is now -42.89% below its all-time high of $332.03 million, reached on 31 December 2021.GLUE Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Working Capital
$209.57 M
-$25.98 M-11.03%
30 September 2024
Summary:
Monte Rosa Therapeutics quarterly working capital is currently $209.57 million, with the most recent change of -$25.98 million (-11.03%) on 30 September 2024. Over the past year, it has increased by +$49.26 million (+30.73%). GLUE quarterly working capital is now -41.43% below its all-time high of $357.78 million, reached on 30 September 2021.GLUE Quarterly Working Capital Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
GLUE Working Capital Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | -24.3% | +30.7% |
| 3 y3 years | +1224.5% | -41.4% |
| 5 y5 years | - | - |
GLUE Working Capital High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -42.9% | +1224.5% | -41.4% | +32.9% |
| 5 y | 5 years | -42.9% | +3368.4% | -41.4% | +1363.9% |
| alltime | all time | -42.9% | +3368.4% | -41.4% | +1363.9% |
Monte Rosa Therapeutics Working Capital History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $209.57 M(-11.0%) |
| June 2024 | - | $235.55 M(+49.3%) |
| Mar 2024 | - | $157.74 M(-16.8%) |
| Dec 2023 | $189.62 M(-24.2%) | $189.62 M(+18.3%) |
| Sept 2023 | - | $160.30 M(-15.2%) |
| June 2023 | - | $189.01 M(-14.1%) |
| Mar 2023 | - | $220.04 M(-12.1%) |
| Dec 2022 | $250.32 M | $250.32 M(-8.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2022 | - | $273.44 M(-3.1%) |
| June 2022 | - | $282.27 M(-8.3%) |
| Mar 2022 | - | $307.88 M(-7.3%) |
| Dec 2021 | $332.03 M(+2219.3%) | $332.03 M(-7.2%) |
| Sept 2021 | - | $357.78 M(+3.0%) |
| June 2021 | - | $347.50 M(+113.7%) |
| Mar 2021 | - | $162.62 M(+1035.9%) |
| Dec 2020 | $14.32 M(+161.9%) | $14.32 M |
| Dec 2019 | $5.47 M | - |
FAQ
- What is Monte Rosa Therapeutics annual working capital?
- What is the all time high annual working capital for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics annual working capital year-on-year change?
- What is Monte Rosa Therapeutics quarterly working capital?
- What is the all time high quarterly working capital for Monte Rosa Therapeutics?
- What is Monte Rosa Therapeutics quarterly working capital year-on-year change?
What is Monte Rosa Therapeutics annual working capital?
The current annual working capital of GLUE is $189.62 M
What is the all time high annual working capital for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high annual working capital is $332.03 M
What is Monte Rosa Therapeutics annual working capital year-on-year change?
Over the past year, GLUE annual working capital has changed by -$60.70 M (-24.25%)
What is Monte Rosa Therapeutics quarterly working capital?
The current quarterly working capital of GLUE is $209.57 M
What is the all time high quarterly working capital for Monte Rosa Therapeutics?
Monte Rosa Therapeutics all-time high quarterly working capital is $357.78 M
What is Monte Rosa Therapeutics quarterly working capital year-on-year change?
Over the past year, GLUE quarterly working capital has changed by +$49.26 M (+30.73%)